Biotechnology: Biological Products (No Diagnostic Substances)

DealsJun 29, 2026, 07:16 AM

REGENXBIO gets $100M milestone from AbbVie for sura-vec trial

AI Summary

REGENXBIO Inc. announced it has earned a $100 million milestone payment from AbbVie Global Enterprises Ltd. This payment was triggered by the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec) for diabetic retinopathy. The payment is expected to be received in July 2026, marking a significant advancement in their collaboration.

Key Highlights

REGENXBIO earned a $100 million milestone payment from AbbVie.
Payment triggered by dosing of first patient in Phase IIb/III NAAVIGATE trial.
Trial is for investigational surabgene lomparvovec (sura-vec) in diabetic retinopathy.
Milestone payment is expected to be received in July 2026.
New long-term data from diabetic retinopathy and wet AMD programs to be presented at ASRS 2026.
Topline data from ATMOSPHERE and ASCENT pivotal trials expected in Q4 2026.

View SEC Filing

RGNX

Biotechnology: Biological Products (No Diagnostic Substances)

REGENXBIO Inc.

Price Impact